NCT07229924 Evaluation of Cognitive Improvement After Bariatric Surgery Using a Virtual Reality Program and the Neuropsi Neuropsychological Battery
| NCT ID | NCT07229924 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospital General de México Dr. Eduardo Liceaga |
| Condition | Obesity (Disorder) |
| Study Type | INTERVENTIONAL |
| Enrollment | 42 participants |
| Start Date | 2024-06-25 |
| Primary Completion | 2025-06-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 42 participants in total. It began in 2024-06-25 with a primary completion date of 2025-06-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background: Obesity is a chronic, systemic, and multifactorial disease affecting populations worldwide, with projections indicating a 50% increase by 2035. It is linked to higher risks of cognitive decline, brain atrophy, and neurodegenerative diseases like Alzheimer's. Bariatric surgery has shown benefits in reducing fat and systemic inflammation, which may improve cognitive function. However, the factors predicting such improvements remain unclear. Objective: To evaluate the effect of bariatric surgery on cognitive performance using virtual reality (Neurotracker) and the Neuropsi neuropsychological battery. Methods: This prospective quasi-experimental study will include patients with morbid obesity who are candidates for bariatric surgery. Cognitive performance will be evaluated using the Neurotracker virtual reality tool and the Neuropsi neuropsychological battery. Participants will complete Neurotracker sessions three times weekly for two weeks before surgery, and again at 3- and 6-months post-surgery. The Neuropsi assessment will be conducted once prior to surgery and repeated at 6 months afterward. Statistical analyses will compare cognitive performance before and after the surgical intervention. Expected Outcomes: The study aims to identify measurable improvements in cognitive function after weight loss from bariatric surgery, evaluated through both traditional neuropsychological tests and immersive virtual reality tools. These results could improve understanding of the cognitive benefits of surgical obesity treatment and the factors that predict these outcomes.
Eligibility Criteria
Inclusion Criteria: A. Age (18-65 years) B. Diagnostic of morbid obesity with a body mass index (BMI) \> 40 kg/m2, or, C. Obesity grade II (BMI \> 35 kg/m2) and associated comorbidities (Diabetes Mellitus type 2, Hypertension, Ischemic Cardiopathy, Hyperlipidemia, Hepatic Steatosis, Metabolic Syndrome, Obstructive Sleep Apnea, Pickwick Syndrome) D. Bariatric surgery criteria. Exclusion Criteria: A. Age \< 18 years, \> 65 years B. Visual impairment C. Personal history of CVE D. Drug addiction.
Contact & Investigator
Argelia Pérez Pacheco, PhD
PRINCIPAL INVESTIGATOR
Hospital General de México Dr. Eduardo Liceaga
Frequently Asked Questions
Who can join the NCT07229924 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Obesity (Disorder). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07229924 currently recruiting?
Yes, NCT07229924 is actively recruiting participants. Contact the research team at argeliapp@ciencias.unam.mx for enrollment information.
Where is the NCT07229924 trial being conducted?
This trial is being conducted at Montreal, Canada, Mexico City, Mexico.
Who is sponsoring the NCT07229924 clinical trial?
NCT07229924 is sponsored by Hospital General de México Dr. Eduardo Liceaga. The principal investigator is Argelia Pérez Pacheco, PhD at Hospital General de México Dr. Eduardo Liceaga. The trial plans to enroll 42 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.